Takeda and Lundbeck’s Trintellix (vortioxetine) Receives MHLW’s Approval for Major Depressive Disorder in Japan

Takeda and Lundbeck’s Trintellix (vortioxetine) Receives MHLW’s Approval for Major Depressive Disorder in Japan

Shots:

  • The MHLW’s approval follows P-III study (NCT02389816) assessing Trintellix (10mg/20mg) vs PBO in 493 patients with recurrent depression in Japan which demonstrated improvement in overall symptoms of depression in adults
  • The NDA submission also follows other three pivotal studies conducted globally (NCT01255787) and in Japan (NCT01355081, NCT01395147), submitted on Sept’2018. In 2007, the companies collaborated to co-develop & co-commercialize Trintellix in Japan
  • Trintellix is a serotonin reuptake inhibitor, regulating neurotransmission via serotonin, norepinephrine, dopamine, acetylcholine and histamine and is an approved therapy in 83 countries including the US, EU and other countries

Click here to­ read full press release/ article | Ref: Takeda | Image: Hines